GENinCode Plc is an AIM listed UK-based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
The Company operates business units in the UK, in the United States through GENinCode U.S. Inc. and in Europe through GENinCode S.L.U.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked in vitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
Placing, Subscription and Retail Offer
On 21st December 2023, the company announced the fundraising by way of a Placing of 67,576,000 New Ordinary Shares, Subscription of 12,424,000 New Ordinary Shares and Retail Offer of up to 20,000,000 New Ordinary Shares.
Having helped GENinCode with the production of their admission document when they floated on AIM in July 2021 and their subsequent annual report, the Perivan shareholder communications team was delighted to work with Cavendish Capital Markets who acted as Nominated Adviser and Broker on documentation which was successfully completed and posted to qualifying shareholders on 22nd December 2023.
Perivan is the market leader for admission document production and specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.